Inhibikase stockholders approve 3M share increase under equity plan and director elections

Inhibikase Therapeutics, Inc.

Stockholders approved amendment to 2020 Equity Incentive Plan increasing authorized shares by 3,000,000.
Certificate of incorporation amended to limit liability of certain officers as permitted by Delaware law.
Arvind Kush (70.3M for) and Dennis Berman (64.1M for) elected as Class III directors to 2029 meeting.
CohnReznick LLP ratified as independent auditor for fiscal 2026 with 106.9M votes for.
Advisory vote on executive compensation passed; company will hold future say-on-pay votes annually.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.